Global Pharmaceutical Intermediate CDMO Market Research Report by Application, by Type of Intermediate, by Drug Type, and by Region Forecast Analysis till 2035

Description

List of Tables

Global Pharmaceutical Intermediate CDMO Market Research Report by Application (Oncology, Cardiovascular Diseases, CNS & Neurological Disorders, Infectious Diseases), by Type of Intermediate [Active Pharmaceutical Ingredients (APIs), Excipients and Additives, Biologics Intermediates, Nucleotide Intermediates], by Drug Type (Generic Drugs, Branded Drugs), and by Region (North America, Europe, South America, Middle East and Africa, and Asia Pacific) Forecast Analysis till 2035

Industry Overview

In 2024, global pharmaceutical intermediate CDMO market was valued at USD 161,798.9 million. It is projected to increase at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2035, reaching USD 346,744.3 million.

The global market for Pharmaceutical Intermediate CDMOs is expanding rapidly due to various contributing factors. Outsourcing by pharmaceutical firms is on the rise as they aim to enhance efficiency and reduce operational burdens. The increasing need for generic drugs and biosimilars, especially in low- and middle-income countries, is a major growth driver. Additionally, advancements in intermediate synthesis technologies and the complex nature of new drug formulations are pushing companies toward specialized CDMO support. The growth of healthcare infrastructure in emerging economies is also enhancing the market landscape.

On the flip side, stringent regulatory compliance requirements and lengthy approval timelines often hamper progress. High capital and operational expenses, intellectual property-related risks, and ongoing supply chain disruptions present notable barriers. A shortage of expertise in advanced chemistry remains another challenge. Despite these issues, the market holds promising opportunities through strategic alliances with biotechnology companies and the increasing demand for tailored, patient-specific medicine solutions.

Industry Segmentations

In terms of application types, the global market is divided into oncology, cardiovascular diseases, CNS and neurological disorders, and infectious disease.

Based on the drug type, global pharmaceutical intermediate CDMO market comprises generic drugs, branded drug.

Global Pharmaceutical intermediate CDMO market has been categorized by type of intermediate, includes active pharmaceutical ingredients (APIS), biologics intermediates, excipients and additives, nucleotide intermediates.

Regionally, global pharmaceutical intermediate CDMO market divided into North America, Europe, South America, Middle East and Africa, and Asia Pacific.

Regional Analysis

The North American market for pharmaceutical intermediate CDMOs is the largest and most sophisticated, with the U.S. leading due to high-tech infrastructure, heavy R&D investments, and FDA-enforced quality regulations. Canada's rising biopharmaceutical industry further supports regional strength.

Europe caters to both domestic powerhouses and global players, emphasizing regulatory compliance, innovation in complex syntheses, and sustainable production practices aligned with circular economy principles.

Asia Pacific, spearheaded by China and India, is witnessing the fastest growth. Cost-effective manufacturing, large-scale facilities, and integrated supply chains enable competitive production of intermediates.

Latin America, while facing diverse regulatory frameworks across countries, is working toward unified standards through regional cooperation. Competitive labor costs and proximity to the U.S. are advantageous, though growth is somewhat hindered by infrastructure constraints.

In the Middle East and Africa, CDMOs largely serve local and neighboring markets by producing intermediates for generic medicines and essential drugs. The region's favorable location between Asia and Europe positions it as a potential hub in pharmaceutical logistics and intermediate supply. As global supply chains evolve, MEA's role may become more pronounced in bridging manufacturing efforts across continents.

Key Players

Thermo Fisher Scientific, Raghava Life Sciences Pvt LTD., Cambrex Corporation, Actylis, Chiracon GmbH, Codexis, Inc., Arkema S.A., Lonza Group AG, Catalent, Inc., Zhejiang Jiuzhou Pharmaceutical Co Ltd are the key competitors of the global pharmaceutical intermediate CDMO market.

1 EXECUTIVE SUMMARY

1.1 MARKET OVERVIEW:
1.2 MARKET SEGMENTATION
1.3 COMPETITIVE LANDSCAPE
1.4 FUTURE OUTLOOK

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 Secondary Research Data Flow:
3.5 PRIMARY RESEARCH:
- 3.5.1 Primary Research DATA FLOW:
- 3.5.2 Primary Research: Number of Interviews conducted
- 3.5.3 Primary Research: Regional Coverage
3.6 APPROACHES FOR MARKET END USER ESTIMATION:
- 3.6.1 Revenue Analysis Approach
- 3.6.2 Data forecasting
- 3.6.3 Data Forecasting Technique
3.7 DATA MODELING
- 3.7.1 microeconomic factor analysis:
- 3.7.2 Data modeling:
3.8 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 Increasing Outsourcing by Pharmaceutical Companies
- 4.2.2 Rising Demand for Generic Drugs and Biosimilars
- 4.2.3 Technological Advancements in Intermediate Synthesis
- 4.2.4 Growing Complexity of Drug Molecules
- 4.2.5 Expansion in Emerging Markets
4.3 RESTRAINTS
- 4.3.1 Stringent Regulatory Compliance and Complex Approval Processes
- 4.3.2 High Operational and Capital Expenditure Costs
- 4.3.3 Property (IP) Risks and Confidentiality Concerns
- 4.3.4 Supply Chain Disruptions and Raw Material Shortages
- 4.3.5 Limited Expertise in Advanced Technologies and Niche Chemistry
4.4 OPPORTUNITY
- 4.4.1 Strategic Partnerships with Biotech Firms
- 4.4.2 Focus on Personalized Medicine Solutions
4.5 IMPACT ANALYSIS OF COVID - 19

5 MARKET FACTOR ANALYSIS

5.1 SUPPLY CHAIN ANALYSIS
- 5.1.1 Raw Material Sourcing & Procurement
- 5.1.2 Research, Development, & Process Optimization
- 5.1.3 Manufacturing & Quality Control
- 5.1.4 Packaging, Storage, & Logistics & Distribution & Customer Delivery
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 Threat of New Entrants (Low to Moderate)
- 5.2.2 Bargaining Power of Suppliers (Moderate)
- 5.2.3 Threat of Substitutes (Low to Moderate)
- 5.2.4 Bargaining Power of Buyers (High)
- 5.2.5 Intensity of Rivalry (High)

6 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE

6.1 INTRODUCTION
6.2 ACTIVE PHARMACEUTICAL INGREDIENTS (APIS)
6.3 EXCIPIENTS & ADDITIVES

7 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE

7.1 INTRODUCTION
7.2 GENERIC DRUGS
7.3 BRANDED DRUGS

8 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION

8.1 INTRODUCTION
8.2 ONCOLOGY
8.3 CARDIOVASCULAR DISEASES
8.4 CNS & NEUROLOGICAL DISORDERS
8.5 INFECTIOUS DISEASES
8.6 OTHERS

9 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION

9.1 GLOBAL
9.2 NORTH AMERICA
- 9.2.1 USA
- 9.2.2 CANADA
9.3 EUROPE
- 9.3.1 united kingdom
- 9.3.2 germany
- 9.3.3 france
- 9.3.4 italy
- 9.3.5 spain
- 9.3.6 RUSSIA
- 9.3.7 rest of europe
9.4 ASIA PACIFIC
- 9.4.1 china
- 9.4.2 South Korea
- 9.4.3 indiA
- 9.4.4 Japan
- 9.4.5 indonesia
- 9.4.6 malaysia
- 9.4.7 thailand
- 9.4.8 rest of asia pacific
9.5 SOUTH AMERICA
- 9.5.1 Mexico
- 9.5.2 Brazil
- 9.5.3 argentina
- 9.5.4 rest of south america
9.6 MIDDEL EAST AND AFRICA
- 9.6.1 gcc countries
- 9.6.2 south africa
- 9.6.3 rest of middle east & africa

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS, 2024SS
10.3 COMPETITOR DASHBOARD

11 COMPANY PROFILES

11.1 RAGHAVA LIFE SCIENCES PVT LTD
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 Key Development
- 11.1.3 SWOT ANALYSIS
- 11.1.4 Key Strategy
11.2 ACTYLIS
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 PRODUCT OFFERED
- 11.2.3 Key Development
- 11.2.4 SWOT ANALYSIS
- 11.2.5 Key Strategy
11.3 CHIRACON GMBH
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 PRODUCT OFFERED
- 11.3.3 SWOT ANALYSIS
- 11.3.4 Key Strategy
11.4 CODEXIS, INC.
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 PRODUCT OFFERED
- 11.4.3 Key Development
- 11.4.4 SWOT ANALYSIS
- 11.4.5 financial analysis
- 11.4.6 Key Strategy
11.5 ARKEMA S.A.
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 PRODUCT OFFERED
- 11.5.3 SWOT ANALYSIS
- 11.5.4 financial analysis
- 11.5.5 Key Strategy
11.6 LONZA GROUP AG
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 PRODUCT OFFERED
- 11.6.3 Key Development
- 11.6.4 SWOT ANALYSIS
- 11.6.5 financial analysis
- 11.6.6 Key Strategy
11.7 THERMO FISHER SCIENTIFIC (PATHEON)
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 PRODUCT OFFERED
- 11.7.3 Key Development
- 11.7.4 SWOT ANALYSIS
- 11.7.5 financial analysis
- 11.7.6 Key Strategy
11.8 CAMBREX CORPORATION
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 PRODUCT OFFERED
- 11.8.3 Key Development
- 11.8.4 SWOT ANALYSIS
- 11.8.5 Key Strategy
11.9 CATALENT, INC.
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 PRODUCT OFFERED
- 11.9.3 Key Development
- 11.9.4 SWOT ANALYSIS
- 11.9.5 financial analysis
- 11.9.6 Key Strategy
11.10 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 PRODUCT OFFERED
- 11.10.3 Key Development
- 11.10.4 SWOT ANALYSIS
- 11.10.5 financial analysis
- 11.10.6 Key Strategy

LIST OF TABLES

TABLE 1 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 2 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 3 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 4 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION, 2019-2035 (USD MILLION)
TABLE 5 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
TABLE 6 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 7 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 8 NORTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 9 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 10 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 11 USA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 12 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 13 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 14 CANADA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 15 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
TABLE 16 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 17 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 18 EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 19 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 20 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 21 UK PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 22 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 23 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 24 GERMANY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 25 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 26 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 27 FRANCE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 28 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 29 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 30 ITALY PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 31 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 32 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 33 SPAIN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 34 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 35 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 36 RUSSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 37 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 38 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 39 REST OF EUROPE PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 40 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
TABLE 41 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 42 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 43 ASIA PACIFIC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 44 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 45 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 46 CHINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 47 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 48 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 49 SOUTH KOREA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 50 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 51 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 52 INDIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 53 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 54 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 55 JAPAN PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 56 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 57 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 58 INDONESIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 59 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 60 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 61 MALAYSIA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 62 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 63 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 64 THAILAND PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 65 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 66 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 67 REST OF APAC PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 68 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO, BY COUNTRY, 2019-2035 (USD MILLION)
TABLE 69 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 70 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 71 SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 72 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 73 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 74 MEXICO PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 75 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 76 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 77 BRAZIL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 78 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 79 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 80 ARGENTINA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 81 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 82 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 83 REST OF SOUTH AMERICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 84 MIDDEL EAST AND AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY COUNTRY, 2019-2035 (USD MILLION)
TABLE 85 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 86 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 87 MIDDLE EAST & AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 88 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 89 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 90 GCC COUNTRIES PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 91 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 92 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 93 SOUTH AFRICA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 94 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2019-2035 (USD MILLION)
TABLE 95 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2019-2035 (USD MILLION)
TABLE 96 REST OF MEA PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2019-2035 (USD MILLION)
TABLE 97 RAGHAVA LIFE SCIENCES PVT LTD: PRODUCT OFFERED
TABLE 98 ACTYLIS: PRODUCT OFFERED
TABLE 99 ACTYLIS: PRODUCT OFFERED
TABLE 100 CHIRACON GMBH: PRODUCT OFFERED
TABLE 101 CODEXIS, INC.: PRODUCT OFFERED
TABLE 102 CODEXIS, INC.: PRODUCT OFFERED
TABLE 103 ARKEMA S.A.: PRODUCT OFFERED
TABLE 104 LONZA GROUP AG: PRODUCT OFFERED
TABLE 105 LONZA GROUP AG: PRODUCT OFFERED
TABLE 106 THERMO FISHER SCIENTIFIC (PATHEON): PRODUCT OFFERED
TABLE 107 THERMO FISHER SCIENTIFIC (PATHEON): PRODUCT OFFERED
TABLE 108 CAMBREX CORPORATION: PRODUCT OFFERED
TABLE 109 CAMBREX CORPORATION: PRODUCT OFFERED
TABLE 110 CATALENT, INC.: PRODUCT OFFERED
TABLE 111 CATALENT, INC.: PRODUCT OFFERED
TABLE 112 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: PRODUCT OFFERED
TABLE 113 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: PRODUCT OFFERED

LIST OF FIGURES

FIGURE 1 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKETSEGMENT
FIGURE 2 DRIVER IMPACT ANALYSIS (2018-2035)
FIGURE 3 RESTRAINT IMPACT ANALYSIS (2018-2035)
FIGURE 4 SUPPLY CHAIN ANALYSIS
FIGURE 5 PORTER'S FIVE FORCES MODEL: GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET
FIGURE 6 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY INTERMEDIATE TYPE, 2024 (% SHARE)
FIGURE 7 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY DRUG TYPE, 2024 (% SHARE)
FIGURE 8 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY APPLICATION, 2024 (% SHARE)
FIGURE 9 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET, BY REGION, 2024 (% SHARE)
FIGURE 10 NORTH AMERICAN MARKET: SWOT ANALYSIS
FIGURE 11 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
FIGURE 12 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
FIGURE 13 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
FIGURE 14 NORTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
FIGURE 15 EUROPE MARKET: SWOT ANALYSIS
FIGURE 16 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
FIGURE 17 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
FIGURE 18 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
FIGURE 19 EUROPE: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
FIGURE 20 ASIA PACIFIC MARKET: SWOT ANALYSIS
FIGURE 21 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
FIGURE 22 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
FIGURE 23 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
FIGURE 24 ASIA PACIFIC: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
FIGURE 25 SOUTH AMERICA MARKET: SWOT ANALYSIS
FIGURE 26 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
FIGURE 27 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
FIGURE 28 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
FIGURE 29 SOUTH AMERICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
FIGURE 30 MIDDEL EAST AND AFRICA: SWOT ANALYSIS
FIGURE 31 MIDDEL EAST AND AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
FIGURE 32 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY COUNTRY, 2024 (% SHARE)
FIGURE 33 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY TYPE, 2024 (% SHARE)
FIGURE 34 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY FREQUENCY, 2024 (% SHARE)
FIGURE 35 MIDDLE EAST & AFRICA: PHARMACEUTICAL INTERMEDIATE CDMO MARKETSHARE, BY APPLICATION, 2024 (% SHARE)
FIGURE 36 GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET: COMPETITIVE ANALSIS, 2024
FIGURE 37 COMPETITOR DASHBOARD: GLOBAL PHARMACEUTICAL INTERMEDIATE CDMO MARKET
FIGURE 38 RAGHAVA LIFE SCIENCES PVT LTD: SWOT ANALYSIS
FIGURE 39 ACTYLIS: SWOT ANALYSIS
FIGURE 40 CHIRACON GMBH: SWOT ANALYSIS
FIGURE 41 CODEXIS, INC.: SWOT ANALYSIS
FIGURE 42 ARKEMA S.A.: SWOT ANALYSIS
FIGURE 43 LONZA GROUP AG: SWOT ANALYSIS
FIGURE 44 THERMO FISHER SCIENTIFIC (PATHEON): SWOT ANALYSIS
FIGURE 45 CAMBREX CORPORATION: SWOT ANALYSIS
FIGURE 46 CATALENT, INC: SWOT ANALYSIS
FIGURE 47 ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTD: SWOT ANALYSIS